FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and aims at predicting efficacy of melanoma immunotherapy with nivolumab. Patient’s tumour tissue is sampled by core biopsy. Tumour-infiltrating lymphocytes (TIL) with a lymphocyte subpopulation are quantified. Lymphoid cells are counted in 10 visual fields. Subpolations of TIL CD45+/CD14-, CD3-CD19+ are determined. Expression level of the intracellular marker Ki67 is examined. At concentration of CD45+/CD14- cells ≥ 4.3 %, CD3-CD19+ cells ≤ 4 % and Si67+ cells ≤ 50 %, the efficacy of melanoma immunotherapy with nivolumab is predicted.
EFFECT: invention provides predicting the effectiveness of melanoma therapy with nivolumab by determining the subpopulation portrait and TIL numerical characteristics.
1 cl, 2 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE PROGNOSIS OF THE EFFECTIVENESS OF BREAST CANCER THERAPY | 2021 |
|
RU2757590C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| TITANIUM IMPLANT WITH THE FUNCTION OF LOCAL IMMUNOTHERAPY FOR OSTEORECONSTRUCTIVE SURGERY AND PREVENTION OF LOCAL RECURRENCE OF ONCOLOGICAL DISEASE AND METHOD FOR ITS MANUFACTURE | 2021 |
|
RU2779367C1 |
| ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 | 2015 |
|
RU2689160C2 |
| METHOD OF OBTAINING A CULTURE OF LYMPHOCYTES ENRICHED IN TUMOR-SPECIFIC T-LYMPHOCYTE CLONES AND CELL CULTURES OBTAINED USING THE SPECIFIED METHOD | 2022 |
|
RU2808595C1 |
| METHOD OF PREDICTING OUTCOME OF ADVANCED CUTANEOUS MELANOMA DURING THERAPY WITH CHECKPOINT INHIBITORS | 2023 |
|
RU2810433C1 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
| BIODEGRADABLE METAL IMPLANT FOR LOCAL IMMUNOTHERAPY OF PATIENTS WITH SOLID TUMORS | 2021 |
|
RU2780927C1 |
